

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCLETIS PHARMA INC.

歌礼制药有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1672)

ANNOUNCEMENT

INSIDE INFORMATION

NEW DRUG APPLICATION FOR ALL-ORAL HCV TREATMENT FILED WITH CHINA FOOD AND DRUG ADMINISTRATION

This announcement is made by Asclepis Pharma Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company is pleased to announce that, the Company has filed the new drug application (the “**NDA**”) for its second Category 1 HCV drug - Ravidasvir (RDV) on July 31, 2018, and expects to receive feedback from the China Food and Drug Administration (the “**CFDA**”) within five business days after the date of the NDA. We will publish a follow-up announcement when we receive such feedback from the CFDA. According to our exclusive licensing agreement with Presidio, the NDA filing triggers our milestone payment obligation to Presidio, which we expect to pay within thirty days of the date of the NDA.

Cautionary Statement required by Rule 18A.05 of the Listing Rules of the Hong Kong Stock Exchange: We cannot guarantee that we will be able to obtain NDA approval for, or ultimately market, Ravidasvir successfully.

By Order of the Board of Directors
Ascletis Pharma Inc.
歌礼制药有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People's Republic of China
July 31, 2018

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; Mr. Wei FU, as non-executive Director; and Dr. Ru Rong JI, Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.